OR AKIVA, Israel, April 28 /PRNewswire-FirstCall/ -- ITGI Medical, Ltd. (TASE: ITGI) a company engaged in research, development, manufacturing and marketing of heterologous tissue covered stents, announced that the US Food and Drug Administration (FDA) has granted HUD (Humanitarian Use Device) designation to Over and Under(R) and Aneugraft(R) Pericardium Covered Stents for treatment of perforations and dissections of native coronary arteries and Saphenous Vein Grafts.
This is the first step towards obtaining marketing approval.
Over and Under(R) and AneuGraft(R) are stents 100% covered with a heterologous tissue, designed to set a barrier between the coronary blood vessel wall and its lumen. Stents are commercially available in Europe, Israel and Latin America for treatment of Saphenous Vein Graft stenosis, aneurysms and for emergency situations such as perforations.
About Pericardium Covered Stents
Pericardium Covered Stents are unique stents covered with heterologous tissue designed to set a barrier between the blood vessel wall and its lumen. Pericardium Covered Stents are indicated for treatment of bypass stenosis, aneurysms and for emergency situations such as perforations.
About ITGI Medical
ITGI medical is engaged in research and development, manufacturing and marketing of heterologous tissue covered stents. ITGI’s stents are already commercially available in Europe, Israel and Latin America. The world stent market has a value estimation of 6.4 Billion USD, of which 37% are generated in the USA.
CONTACT: Danna Moran, VP Marketing, ITGI Medical Ltd., P: +972-72-2200335,
dannam@itgimedical.com
